Borja de Lacy

Borja de Lacy

Auto-generated profile, based on publicly available information

Borja de Lacy

Gastrointestinal Surgery Department, Hospital Clínic of Barcelona, University of Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in British Journal of Surgery
Verified
Journal Article
Open access
PDF file
GZGloria Zaffaroni
Gloria Zaffaroni
Alessandro MannucciAlessandro Mannucci
Alessandro Mannucci
LKLaura Koskenvuo
Laura Koskenvuo
BLBorja de Lacy
Borja de Lacy
AMAnna Maffioli
Anna Maffioli
GMGabriela Möslein
Gabriela Möslein
Hereditary adenomatous polyposis syndromes, including familial adenomatous polyposis and other rare adenomatous polyposis syndromes, increase the lifetime risk of colorectal and other cancers. A team of 38 experts convened to update the 2008 European recommendations for the clinical management of patients with adenomatous polyposis syndromes. Additionally, other rare monogenic adenomatous polyposis syndromes were reviewed and added. Eighty-nine clinically relevant questions were answered after a systematic review of the existing literature with grading of the evidence according to Grading of Recommendations, Assessment, Development, and Evaluation methodology. Two levels of consensus were identified: consensus threshold (≥67% of voting guideline committee members voting either ‘Strongly agree’ or ‘Agree’ during the Delphi rounds) and high threshold (consensus ≥ 80%). One hundred and forty statements reached a high level of consensus concerning the management of hereditary adenomatous polyposis syndromes. These updated guidelines provide current, comprehensive, and evidence-based practical recommendations for the management of surveillance and treatment of familial adenomatous polyposis patients, encompassing additionally MUTYH-associated polyposis, gastric adenocarcinoma and proximal polyposis of the stomach and other recently identified polyposis syndromes based on pathogenic variants in other genes than APC or MUTYH. Due to the rarity of these diseases, patients should be managed at specialized centres.

3 November 2017 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
FLF. Borja de Lacy
F. Borja de Lacy
JLJacqueline J. E. M. van Laarhoven
Jacqueline J. E. M. van Laarhoven
RPRomina Pena
Romina Pena
MAMaría Clara Arroyave
María Clara Arroyave
RBRaquel Bravo
Raquel Bravo
ALAntonio M. Lacy
Antonio M. Lacy

1 September 2023 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
YGYoelimar Guzmán
Yoelimar Guzmán
JRJosé Ríos
José Ríos
JPJesús Paredes
Jesús Paredes
PDPaula Domínguez
Paula Domínguez
JMJoan Maurel
Joan Maurel
FLF. Borja de Lacy
F. Borja de Lacy
The criterion standard treatment for mid and distal locally advanced rectal cancer is total mesorectal excision (TME).1 Evidence supports the addition of neoadjuvant therapy (NAT) in selected cases, which include extramural venous invasion (EMVI), threatened circumferential resection margin (CRM), cancer stages cT3 to T4, or node-positive tumors. The main objective of NAT is to reduce tumor burden and facilitate downstaging, increasing the possibility of achieving higher rates of R0 (ie, surgical margin microscopically negative for residual tumor) resections.2,3 Patients with good response to NAT may benefit from sphincter-saving procedures or even an active surveillance strategy (watch and wait), thus avoiding surgical comorbidities.4-7

20 July 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
FLF. B. de Lacy
F. B. de Lacy
SRS. X. Roodbeen
S. X. Roodbeen
JRJ. Ríos
J. Ríos
JLJ. van Laarhoven
J. van Laarhoven
AOA. Otero-Piñeiro
A. Otero-Piñeiro
ALA. M. Lacy
A. M. Lacy
Background: For patients with mid and distal rectal cancer, robust evidence on long-term outcome and causal treatment effects of transanal total mesorectal excision (TaTME) is lacking. This multicentre retrospective cohort study aimed to assess whether TaTME reduces locoregional recurrence rate compared to laparoscopic total mesorectal excision (LapTME). Methods: Consecutive patients with rectal cancer within 12 cm from the anal verge and clinical stage II-III were selected from three institutional databases. Outcome after TaTME (Nov 2011 - Feb 2018) was compared to a historical cohort of patients treated with LapTME (Jan 2000 - Feb 2018) using the inverse probability of treatment weights method. The primary endpoint was three-year locoregional recurrence. Results: A total of 710 patients were analysed, 344 in the TaTME group and 366 in the LapTME group. At 3 years, cumulative locoregional recurrence rates were 3.6% (95% CI, 1.1–6.1) in the TaTME group and 9.6% (95% CI, 6.5–12.7) in the LapTME group (HR = 0.4; 95% CI, 0.23–0.69; p = 0.001). Three-year cumulative disease-free survival rates were 74.3% (95% CI, 68.8–79.8) and 68.6% (95% CI, 63.7–73.5) (HR = 0.82; 95% CI, 0.65–1.02; p = 0.078) and three-year overall survival 87.2% (95% CI, 82.7–91.7) and 82.2% (95% CI, 78.0–86.2) (HR = 0.74; 95% CI, 0.53–1.03; p = 0.077), respectively. In patients who underwent sphincter preservation procedures, TaTME was associated with a significantly better disease-free survival (HR = 0.78; 95% CI, 0.62–0.98; p = 0.033). Conclusions: These findings suggest that TaTME may improve locoregional recurrence and disease-free survival rates among patients with mid and distal locally advanced rectal cancer.

23 January 2019 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
FLF. Borja de Lacy
F. Borja de Lacy
DKDeborah Susan Keller
Deborah Susan Keller
BMBeatriz Martin-Perez
Beatriz Martin-Perez
SESameh Hany Emile
Sameh Hany Emile
MCManish Chand
Manish Chand
ALAntonio M. Lacy
Antonio M. Lacy

27 July 2023 in Annals of Surgery
Verified
Journal Article
Open access
NGNynke G. Greijdanus
Nynke G. Greijdanus
KWKiedo Wienholts
Kiedo Wienholts
SUSander Ubels
Sander Ubels
KTKevin Talboom
Kevin Talboom
GHGerjon Hannink
Gerjon Hannink
TGTENTACLE-Rectum Collaborative Group
TENTACLE-Rectum Collaborative Group
Objective: To develop and validate a prediction model (STOMA score) for 1-year stoma-free survival in patients with rectal cancer (RC) with anastomotic leakage (AL). Background: AL after RC resection often results in a permanent stoma. Methods: This international retrospective cohort study (TENTACLE-Rectum) encompassed 216 participating centres and included patients who developed AL after RC surgery between 2014 and 2018. Clinically relevant predictors for 1-year stoma-free survival were included in uni and multivariable logistic regression models. The STOMA score was developed and internally validated in a cohort of patients operated between 2014 and 2017, with subsequent temporal validation in a 2018 cohort. The discriminative power and calibration of the models’ performance were evaluated. Results: This study included 2499 patients with AL, 1954 in the development cohort and 545 in the validation cohort. Baseline characteristics were comparable. One-year stoma-free survival was 45.0% in the development cohort and 43.7% in the validation cohort. The following predictors were included in the STOMA score: sex, age, American Society of Anestesiologist classification, body mass index, clinical M-disease, neoadjuvant therapy, abdominal and transanal approach, primary defunctioning stoma, multivisceral resection, clinical setting in which AL was diagnosed, postoperative day of AL diagnosis, abdominal contamination, anastomotic defect circumference, bowel wall ischemia, anastomotic fistula, retraction, and reactivation leakage. The STOMA score showed good discrimination and calibration (c-index: 0.71, 95% CI: 0.66–0.76). Conclusions: The STOMA score consists of 18 clinically relevant factors and estimates the individual risk for 1-year stoma-free survival in patients with AL after RC surgery, which may improve patient counseling and give guidance when analyzing the efficacy of different treatment strategies in future studies.